NanoBase™ Rx: The Pharmacy Compounding Industry's Full Replacement for HLB Chemistry
NanoBase™ Rx is a delivery architecture excipient. It is not a finished drug product, a compounded preparation, or an active pharmaceutical ingredient. The compounding pharmacy is the licensed entity that sources APIs through legitimate wholesale channels and incorporates them into the NanoBase™ Rx vehicle under its own USP Chapter 795 or 797 quality program. Every technical claim below refers to the excipient vehicle and to surrogate loaded systems tested internally. None of it substitutes for the pharmacy's own finished preparation studies.
NanoBase™ Rx is the first pharmacy compounding excipient to productize a tri-domain nano-delivery architecture co-organized within a lyotropic liquid crystal matrix for the US 503A and 503B compounding market. The two architectures already existed separately. Tri-domain nano-carrier systems have appeared in cosmeceutical and topical literature. Lyotropic liquid crystal vehicles have appeared in controlled release research and in a small number of pharmaceutical niche products. No commercial compounding excipient on the US market has combined them into a single supplied vehicle with stability data, compatibility screening, and USP grade documentation suitable for a compounding pharmacy to adopt in place of HLB governed PLO. That is the specific claim. We do not claim to have invented either tri-domain nano-delivery or liquid crystal pharmaceutics. We claim to be the first to integrate both into a single supplied excipient for this market.
The compounding vehicle problem nobody wants to name
Compounding pharmacy has been running on an excipient chemistry that was never designed for bioavailability. The Hydrophilic-Lipophilic Balance (HLB) system, drafted by William Griffin in 1949 for industrial surfactant selection, remains the de facto rulebook for almost every transdermal base, PLO gel, cream, and ointment vehicle currently used in compounding. HLB tells a compounder how to stabilize a macro-scale emulsion. It does not tell the compounder whether a loaded API will cross the stratum corneum at a clinically meaningful rate, whether it will remain chemically intact in the vehicle across a 90 day beyond use date, or whether the patient will receive a reproducible dose from application one to application thirty.
NanoBase™ Rx replaces HLB excipient chemistry entirely by operating on two physical principles that HLB does not address: nano-scale particle engineering and lyotropic liquid crystal phase organization.
What the tri-domain architecture actually means
NanoBase™ Rx resolves the loading problem of HLB vehicles through three engineered nano-domains operating in parallel within a single supplied excipient:
1. A lipophilic nano-domain, mean particle diameter 40 to 90 nm validated by dynamic light scattering, that the compounding pharmacy can load with oil soluble APIs across a logP range of roughly 3.0 to 5.5.
2. A hydrophilic nano-domain capable of carrying water soluble APIs across a logP range of roughly minus 1.0 to 3.0 without the aqueous phase destabilizing the lipid phase.
3. An interfacial bridging domain composed of engineered amphiphilic nano carriers that shuttle loaded actives across the stratum corneum intercellular lipid matrix rather than simply sitting on it.
Those three nano-domains solve the loading and transport problem. They do not by themselves solve the thermodynamic stability problem, the BUD problem, or the skin phase-coupling problem. That is what the liquid crystal layer is for.
What the liquid crystal architecture adds
The three nano-domains of NanoBase™ Rx are co-organized within a lyotropic liquid crystal matrix. Depending on water content and temperature range, the matrix expresses lamellar phase organization (Lα) and bicontinuous cubic phase organization (Q). These are not incidental structures. They are the actual reason NanoBase™ Rx behaves the way it does on the skin and on the shelf.
Biomimetic phase matching at the stratum corneum. Stratum corneum intercellular lipids exist natively in a liquid crystalline lamellar gel phase. An HLB governed emulsion sits on top of that phase as a foreign droplet structure. A lyotropic lamellar vehicle couples into it. Phase coupling, rather than phase boundary resistance, is the physical explanation for why lyotropic lamellar systems transport loaded actives more efficiently into the intercellular lipid domain. NanoBase™ Rx is engineered specifically to present a lamellar face to the stratum corneum at the moment of application.
Bicontinuous cubic phase as a reservoir. The bicontinuous cubic phase exhibits a bi-continuous water and lipid channel network with an internal surface area on the order of hundreds of square meters per gram. That surface area is the loading reservoir for the hydrophilic and lipophilic nano-domains. It is also the kinetic reason for the sustained release profile NanoBase™ Rx delivers relative to a PLO gel.
Thermodynamic stability rather than kinetic emulsion stability. An HLB emulsion is kinetically stable. Given enough time, temperature stress, or shear, it will phase separate. A lyotropic liquid crystal phase is thermodynamically stable within its phase window. It does not separate because it is not trying to resist separation in the first place. This is the core reason NanoBase™ Rx maintains particle-size and phase stability across 180 days at 25 degrees C under ICH accelerated conditions, while PLO typically begins visible phase separation at 30 to 45 days.
Mechanical robustness. Lyotropic cubic and lamellar phases tolerate shear stress, mixing during compounding, and patient-induced shear at the skin surface without collapsing their internal architecture. That is why a pharmacy can load, mill, and fill NanoBase™ Rx on existing compounding equipment without destroying the vehicle.
Why HLB has always been the wrong tool for compounding
HLB was built to answer one question: which surfactant will emulsify this oil in this water. It was never built to answer the questions a prescribing physician actually cares about once a compounding pharmacy has dispensed the finished preparation:
What percentage of the applied dose reaches systemic circulation.
How reproducible that percentage is across patients, application sites, and batch to batch variation.
How long a loaded API remains assayable at label potency in the vehicle.
Whether the excipient itself introduces irritation, sensitization, or microbial risk over a typical 30, 60, or 90 day BUD.
Every HLB based compounding vehicle, including every PLO variant on the market, is an educated guess at these four questions because HLB as a framework cannot answer them. NanoBase™ Rx answers the excipient side of those questions with characterization data generated at Pensive Beauty Labs: DLS particle size distribution on the nano-domains, small angle X-ray scattering consistent with lamellar and bicontinuous cubic phase assignment, zeta potential for electrostatic stability, HPLC assay of the unloaded vehicle at T0 and T180, Franz cell permeation studies using surrogate model compounds across the logP range, and USP 51 preservative efficacy testing. The pharmacy completes its own finished preparation stability study on top of this excipient characterization package under its own USP 795 or 797 program. We document the vehicle. The pharmacy documents the finished preparation.
What NanoBase™ Rx does for a 503A or 503B pharmacy
Compounding pharmacies competing on price are losing. Pharmacies competing on clinical outcomes and prescriber confidence are winning. NanoBase™ Rx shifts a compounding operation from the former to the latter.
Single excipient, broad formulary. One validated tri-domain plus liquid crystal vehicle covers the hormone panel, the pain panel, the dermatologic panel, and the neuro panel. Inventory complexity drops at the excipient shelf. Compounding error rates drop with it.
Extended BUD defensibility. USP Chapter 795 requires BUD assignment supported by stability indicating data or a conservative default. The thermodynamic stability of the liquid crystal phase is the scientific basis that lets partner pharmacies move from a default 30 day BUD to documented 90 day and 180 day BUDs on specific finished preparations, backed by the Pensive Beauty excipient stability package combined with the pharmacy's own finished preparation testing.
Prescriber trust. A physician who receives a reproducible transdermal hormone preparation will prescribe a second. A physician who receives three inconsistent batches will not. NanoBase™ Rx removes batch to batch vehicle variability as a clinical confounding factor, leaving only the pharmacy's loading technique to control.
Patient adherence. Lamellar phase lyotropic vehicles do not feel like PLO. They absorb in seconds, leave no residue, and carry no lecithin odor. Adherence data on transdermal therapy correlates directly with vehicle cosmetic acceptability. NanoBase™ Rx wins this comparison in every blind panel we have run using unloaded placebo vehicle.
503B scalability. For outsourcing facilities registered under FDA 503B, NanoBase™ Rx scales under the same cGMP framework the facility already operates. No new equipment class. No novel excipient filings required. The nano carriers and the liquid crystal forming lipids are constructed from pharmacopeial grade materials already cleared for topical and transdermal use.
API compatibility matrix
NanoBase™ Rx has been characterized for excipient compatibility with the following API classes and logP ranges. Pensive Beauty does not supply, compound, or distribute any API on this list. The compounding pharmacy sources each API through its own legitimate wholesale channel and incorporates it into the NanoBase™ Rx vehicle under its own quality program. Classes marked with an asterisk have published internal surrogate flux data available on request under NDA.
Hormones: progesterone USP, estradiol USP, testosterone USP, DHEA*, pregnenolone. LogP range 3.0 to 5.5.
Analgesics and NSAIDs: ketoprofen*, diclofenac sodium, ibuprofen, flurbiprofen, meloxicam. LogP range 2.5 to 4.5.
Neuromodulators: ketamine HCl*, gabapentin, baclofen*, amitriptyline HCl, clonidine. LogP range minus 1.0 to 3.0.
Local anesthetics: lidocaine HCl*, lidocaine base, prilocaine, tetracaine, benzocaine. LogP range 1.5 to 3.0.
Antifungals: ketoconazole, clotrimazole, terbinafine. LogP range 3.5 to 5.5.
Muscle relaxants: cyclobenzaprine HCl, orphenadrine citrate, methocarbamol.
Dermatologic actives: tretinoin USP*, hydroquinone USP, kojic acid, azelaic acid USP, tranexamic acid.
Compatibility beyond this list is determinable via a 30 day compatibility screen on the pharmacy's own API sample at the Pensive Beauty lab. We do not guess. We test the vehicle against the API the pharmacy provides.
Why we can say "the only full replacement for HLB" and mean it
A full replacement compounding excipient has to meet five criteria simultaneously:
1. It must accept polar and nonpolar APIs in a single continuous vehicle, loaded by the pharmacy, without phase separation.
2. It must transport those loaded APIs across the stratum corneum at a flux rate that HLB governed emulsions cannot achieve at the same drug load.
3. It must remain particle size stable and phase stable through the entire assigned BUD, documented by DLS on the unloaded vehicle and on surrogate loaded systems, with small angle scattering data supporting the phase assignment.
4. It must present a biomimetic liquid crystalline interface to the stratum corneum rather than a foreign emulsion boundary.
5. It must be manufacturable at both 503A compounding pharmacy scale and 503B outsourcing scale using standard pharmaceutical equipment.
NanoBase™ Rx meets all five. No other excipient on the US compounding market, PLO or otherwise, meets all five, and no competing product combines tri-domain nano-delivery with lyotropic liquid crystal phase organization. This is a verifiable claim about a vehicle, not about a drug product. We invite any compounding pharmacy, any 503B outsourcing facility, and any industry chemist to request the excipient characterization package and test the vehicle against their own APIs.
How to onboard a pharmacy to NanoBase™ Rx
The onboarding process is deliberate and it is excipient focused. Pensive Beauty Nanoscience Labs is a contract nanoscience lab, not a bulk API supplier, not a compounding pharmacy, and not a 503B outsourcing facility. We enter an excipient supply relationship with the pharmacy, transfer validated vehicle monographs, supply the base under a quality agreement, and provide excipient stability and phase characterization data. The pharmacy's own Pharmacist in Charge remains responsible for API sourcing, API level compatibility review, finished preparation stability, BUD assignment, and dispensing under state and federal authority. A discovery call, a signed NDA, and a monograph walkthrough are the first three steps.
Pharmacies that onboard typically retire their PLO line within six months. The economics, the clinical outcomes, and the prescriber feedback drive that decision without our having to make the argument.
The call to the industry
Pharmaceutical compounding has been patient with HLB for seventy five years. Patients have been less patient. Prescribers have been less patient. Payers are running out of patience entirely. A compounding pharmacy that can document flux, reproducibility, stability, phase assignment, and BUD with nano scale and liquid crystal characterization data on its vehicle will own the next decade of this industry. A compounding pharmacy still defending PLO on a 1949 surfactant table will not.
NanoBase™ Rx is the excipient tool. Pensive Beauty Labs is the excipient partner. The compounding pharmacy is the clinical authority. The only remaining question is which side of the excipient transition your pharmacy ends up on.
Ready to evaluate NanoBase™ Rx for your formulary? Book a discovery call with Pensive Beauty Labs and request the full excipient characterization, phase assignment, and compatibility package.
NanoBase™ and NanoBase™ Rx are trademarks of Pensive Beauty, LLC. Pensive Beauty, LLC is an contract nanoscience laboratory. Pensive Beauty does not manufacture, compound, repackage, distribute, prescribe, or dispense any active pharmaceutical ingredient or finished drug product. All characterization claims refer to the NanoBase™ Rx excipient vehicle and surrogate loaded systems tested internally. Phase assignment is based on small angle scattering data consistent with lamellar and bicontinuous cubic lyotropic liquid crystal phases under the specified water content and temperature conditions. Compounded preparation claims, BUD assignment, and dispensing remain the exclusive responsibility of the licensed compounding pharmacy under applicable USP, state, and federal authority.
